Checkpoint Therapeutics (CKPT) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart

CKPT Stock Forecast

Checkpoint Therapeutics stock forecast is as follows: a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.

CKPT Analyst Ratings

Buy

According to 3 Wall Street analysts, Checkpoint Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for CKPT stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Dec 19, 2022	B. Riley Securities	Buy	Buy	Hold
Jun 09, 2021	B. Riley	-	Buy	Initialise
Jan 22, 2021	Cantor Fitzgerald	-	Overweight	Initialise

Row per page

Go to

Checkpoint Therapeutics's last stock rating was published by B. Riley Securities on Dec 19, 2022. The company gave CKPT a "Buy" rating, the same as its previous rate.

Checkpoint Therapeutics Financial Forecast

Checkpoint Therapeutics Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
Revenue	-	-	-	-	-	-	-	-	$6.00K	$31.00K	-	$35.00K	$74.00K	$48.00K	$18.00K	$52.00K	-	$29.00K	$155.00K	$68.00K	$27.00K	$28.00K	$42.00K	$972.00K	$25.00K	$280.00K	$1.05M	$352.00K	$343.00K	$693.00K
Avg Forecast	$31.46M	$22.03M	$15.03M	$4.53M	$10.33K	$20.33K	$15.50K	$20.33K	$30.00K	$16.67K	$5.00K	$12.50K	$40.00K	$23.33K	$17.50K	$23.33K	$70.00K	$114.00K	$114.00K	$142.50K	$82.50K	$193.33K	$393.33K	$576.67K	$400.00K	$566.67K	$740.00K	$1.18M	$318.35K	$862.50K
High Forecast	$31.46M	$22.03M	$15.03M	$4.53M	$10.33K	$20.33K	$15.50K	$20.50K	$30.00K	$16.67K	$5.00K	$12.50K	$40.00K	$23.33K	$17.50K	$23.33K	$70.00K	$114.00K	$114.00K	$142.50K	$82.50K	$193.33K	$393.33K	$576.67K	$400.00K	$566.67K	$740.00K	$1.18M	$382.01K	$1.03M
Low Forecast	$31.46M	$22.03M	$15.03M	$4.53M	$10.33K	$20.33K	$15.50K	$20.17K	$30.00K	$16.67K	$5.00K	$12.50K	$40.00K	$23.33K	$17.50K	$23.33K	$70.00K	$114.00K	$114.00K	$142.50K	$82.50K	$193.33K	$393.33K	$576.67K	$400.00K	$566.67K	$740.00K	$1.18M	$254.68K	$690.00K
# Analysts	1	1	1	1	3	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	9	9	9	9	8	8	8	8	10	13
Surprise %	-	-	-	-	-	-	-	-	0.20%	1.86%	-	2.80%	1.85%	2.06%	1.03%	2.23%	-	0.25%	1.36%	0.48%	0.33%	0.14%	0.11%	1.69%	0.06%	0.49%	1.42%	0.30%	1.08%	0.80%

Checkpoint Therapeutics's average Quarter revenue forecast for Mar 24 based on 1 analysts is $20.33K, with a low forecast of $20.17K, and a high forecast of $20.50K. CKPT's average Quarter revenue forecast represents a 238.88% increase compared to the company's last Quarter revenue of $6.00K (Dec 23).

Checkpoint Therapeutics EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	1	3	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	9	9	9	9	8	8	8	8	10	13
EBITDA	-	-	-	-	-	-	-	-	$-10.17M	$-7.70M	$-16.20M	$-25.65M	$-16.64M	$-10.66M	$-14.16M	$-16.86M	$-29.76M	$-11.27M	$-9.14M	$-6.50M	$-10.22M	$-4.93M	$-4.64M	$-3.28M	$-8.83M	$-5.21M	$-4.79M	$-5.89M	$-8.77M	$-4.38M
Avg Forecast	$-31.46M	$-22.03M	$-15.03M	$-4.53M	$-10.33K	$-20.33K	$-15.50K	$-20.33K	$-30.00K	$-16.67K	$-5.00K	$-12.50K	$-40.00K	$-23.33K	$-17.50K	$-10.58M	$-70.00K	$-114.00K	$-114.00K	$-7.16M	$-82.50K	$-193.33K	$-393.33K	$-4.54M	$-400.00K	$-566.67K	$-740.00K	$-7.85M	$-8.09M	$-5.26M
High Forecast	$-31.46M	$-22.03M	$-15.03M	$-4.53M	$-10.33K	$-20.33K	$-15.50K	$-20.17K	$-30.00K	$-16.67K	$-5.00K	$-12.50K	$-40.00K	$-23.33K	$-17.50K	$-8.47M	$-70.00K	$-114.00K	$-114.00K	$-5.72M	$-82.50K	$-193.33K	$-393.33K	$-3.63M	$-400.00K	$-566.67K	$-740.00K	$-6.28M	$-6.47M	$-4.21M
Low Forecast	$-31.46M	$-22.03M	$-15.03M	$-4.53M	$-10.33K	$-20.33K	$-15.50K	$-20.50K	$-30.00K	$-16.67K	$-5.00K	$-12.50K	$-40.00K	$-23.33K	$-17.50K	$-12.70M	$-70.00K	$-114.00K	$-114.00K	$-8.59M	$-82.50K	$-193.33K	$-393.33K	$-5.45M	$-400.00K	$-566.67K	$-740.00K	$-9.42M	$-9.70M	$-6.31M
Surprise %	-	-	-	-	-	-	-	-	338.97%	462.05%	3239.00%	2051.92%	416.10%	457.04%	809.37%	1.59%	425.09%	98.82%	80.21%	0.91%	123.94%	25.50%	11.81%	0.72%	22.07%	9.19%	6.48%	0.75%	1.08%	0.83%

undefined analysts predict CKPT's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Checkpoint Therapeutics's previous annual EBITDA (undefined) of $NaN.

Checkpoint Therapeutics Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	1	3	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	9	9	9	9	8	8	8	8	10	13
Net Income	-	-	-	-	-	-	-	-	$-19.13M	$-5.72M	$-16.52M	$-2.87M	$-25.36M	$-10.51M	$-14.10M	$-16.82M	$-29.74M	$-11.27M	$-9.14M	$-6.50M	$-10.22M	$-4.93M	$-4.64M	$-3.28M	$-8.83M	$-5.21M	$-4.79M	$-5.89M	$-8.77M	$-4.38M
Avg Forecast	$6.04M	$5.61M	$3.02M	$-4.32M	$-7.62M	$-6.33M	$-13.16M	$-11.81M	$-24.81M	$-32.80M	$-33.14M	$-44.97M	$-53.68M	$-50.22M	$-59.17M	$-10.59M	$-56.25M	$-49.68M	$-37.99M	$-7.16M	$-29.22M	$-29.22M	$-32.87M	$-4.54M	$-60.88M	$-60.88M	$-57.53M	$-7.85M	$-8.09M	$-5.26M
High Forecast	$6.04M	$5.61M	$3.02M	$-4.32M	$-7.62M	$-6.33M	$-13.16M	$-11.81M	$-22.47M	$-32.80M	$-33.14M	$-44.97M	$-53.68M	$-50.22M	$-59.17M	$-8.47M	$-56.25M	$-49.68M	$-37.99M	$-5.72M	$-29.22M	$-29.22M	$-32.87M	$-3.63M	$-60.88M	$-60.88M	$-57.53M	$-6.28M	$-6.47M	$-4.21M
Low Forecast	$6.04M	$5.61M	$3.02M	$-4.32M	$-7.62M	$-6.33M	$-13.16M	$-11.81M	$-26.82M	$-32.80M	$-33.14M	$-44.97M	$-53.68M	$-50.22M	$-59.17M	$-12.71M	$-56.25M	$-49.68M	$-37.99M	$-8.59M	$-29.22M	$-29.22M	$-32.87M	$-5.45M	$-60.88M	$-60.88M	$-57.53M	$-9.42M	$-9.70M	$-6.31M
Surprise %	-	-	-	-	-	-	-	-	0.77%	0.17%	0.50%	0.06%	0.47%	0.21%	0.24%	1.59%	0.53%	0.23%	0.24%	0.91%	0.35%	0.17%	0.14%	0.72%	0.14%	0.09%	0.08%	0.75%	1.08%	0.83%

Checkpoint Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. CKPT's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Checkpoint Therapeutics SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	1	3	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	9	9	9	9	8	8	8	8	10	13
SG&A	-	-	-	-	-	-	-	-	$1.88M	$2.24M	$2.28M	$2.29M	$2.48M	$1.85M	$2.13M	$2.24M	$2.13M	$1.92M	$2.11M	$2.37M	$2.12M	$2.43M	$1.69M	$1.68M	$2.15M	$1.62M	$1.76M	$1.70M	$2.19M	$1.40M
Avg Forecast	$1.09B	$762.86M	$520.47M	$156.89M	$357.80K	$704.06K	$536.71K	$704.06K	$1.04M	$577.12K	$173.13K	$432.83K	$1.39M	$807.94K	$605.96K	$807.94K	$2.42M	$3.95M	$3.95M	$4.93M	$2.86M	$6.69M	$13.62M	$19.97M	$13.85M	$19.62M	$25.62M	$40.82M	$11.02M	$29.87M
High Forecast	$1.09B	$762.86M	$520.47M	$156.89M	$357.83K	$704.06K	$536.71K	$709.81K	$1.04M	$577.12K	$173.13K	$432.83K	$1.39M	$807.94K	$605.96K	$807.94K	$2.42M	$3.95M	$3.95M	$4.93M	$2.86M	$6.69M	$13.62M	$19.97M	$13.85M	$19.62M	$25.62M	$40.82M	$13.23M	$35.84M
Low Forecast	$1.09B	$762.86M	$520.47M	$156.89M	$357.73K	$704.06K	$536.71K	$698.28K	$1.04M	$577.12K	$173.13K	$432.83K	$1.39M	$807.94K	$605.96K	$807.94K	$2.42M	$3.95M	$3.95M	$4.93M	$2.86M	$6.69M	$13.62M	$19.97M	$13.85M	$19.62M	$25.62M	$40.82M	$8.82M	$23.89M
Surprise %	-	-	-	-	-	-	-	-	1.81%	3.87%	13.17%	5.30%	1.79%	2.28%	3.51%	2.78%	0.88%	0.49%	0.54%	0.48%	0.74%	0.36%	0.12%	0.08%	0.16%	0.08%	0.07%	0.04%	0.20%	0.05%

Checkpoint Therapeutics's average Quarter SG&A projection for Mar 24 is $704.06K, based on 1 Wall Street analysts, with a range of $698.28K to $709.81K. The forecast indicates a -62.47% fall compared to CKPT last annual SG&A of $1.88M (Dec 23).

Checkpoint Therapeutics EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	1	3	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	9	9	9	9	8	8	8	8	10	13
EPS	-	-	-	-	-	-	-	-	$-0.69	$-0.29	$-0.00	$-0.24	$-2.87	$-1.19	$-1.61	$-1.98	$-3.79	$-1.43	$-1.21	$-0.93	$-1.81	$-0.87	$-0.90	$-0.64	$-1.73	$-1.51	$-1.47	$-1.83	$-3.54	$-1.99
Avg Forecast	$0.14	$0.13	$0.07	$-0.10	$-0.18	$-0.15	$-0.30	$-0.27	$-0.57	$-0.76	$-0.77	$-1.04	$-1.24	$-1.38	$-1.62	$-1.35	$-1.54	$-1.36	$-1.04	$-1.05	$-0.80	$-0.80	$-0.90	$-1.27	$-1.67	$-1.67	$-1.57	$-2.70	$-0.18	$-0.30
High Forecast	$0.14	$0.13	$0.07	$-0.10	$-0.18	$-0.15	$-0.30	$-0.27	$-0.52	$-0.76	$-0.77	$-1.04	$-1.24	$-1.38	$-1.62	$-1.35	$-1.54	$-1.36	$-1.04	$-1.05	$-0.80	$-0.80	$-0.90	$-1.27	$-1.67	$-1.67	$-1.57	$-2.70	$-0.15	$-0.24
Low Forecast	$0.14	$0.13	$0.07	$-0.10	$-0.18	$-0.15	$-0.30	$-0.27	$-0.62	$-0.76	$-0.77	$-1.04	$-1.24	$-1.38	$-1.62	$-1.35	$-1.54	$-1.36	$-1.04	$-1.05	$-0.80	$-0.80	$-0.90	$-1.27	$-1.67	$-1.67	$-1.57	$-2.70	$-0.22	$-0.36
Surprise %	-	-	-	-	-	-	-	-	1.20%	0.38%	0.00%	0.23%	2.31%	0.87%	0.99%	1.47%	2.46%	1.05%	1.16%	0.88%	2.27%	1.09%	1.00%	0.51%	1.04%	0.90%	0.93%	0.68%	19.67%	6.62%

According to undefined Wall Street analysts, Checkpoint Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to CKPT previous annual EPS of $NaN (undefined).

Checkpoint Therapeutics Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
RVPH	Reviva Pharmaceuticals	$1.13	$10.00	784.96%	Buy
SPRO	Spero Therapeutics	$1.18	$10.00	747.46%	Buy
CTMX	CytomX Therapeutics	$0.91	$5.73	529.67%	Buy
ATXI	Avenue Therapeutics	$1.93	$12.00	521.76%	Buy
CKPT	Checkpoint Therapeutics	$3.43	$20.00	483.09%	Buy
KOD	Kodiak Sciences	$5.53	$31.60	471.43%	Buy
LUMO	Lumos Pharma	$4.33	$16.50	281.06%	Buy
CUE	Cue Biopharma	$1.25	$4.33	246.40%	Buy
TIL	Instil Bio	$26.50	$78.25	195.28%	Hold
ASMB	Assembly Biosciences	$16.14	$35.50	119.95%	Buy
ACHL	Achilles Therapeutics	$1.05	$2.00	90.48%	Buy

CKPT Forecast FAQ

Is Checkpoint Therapeutics a good buy?

Yes, according to 3 Wall Street analysts, Checkpoint Therapeutics (CKPT) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of CKPT's total ratings.

What are Checkpoint Therapeutics's analysts' financial forecasts?

Checkpoint Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $66.5K (high $66.67K, low $66.33K), average EBITDA is $-66.499K (high $-66.33K, low $-66.666K), average net income is $-38.925M (high $-38.925M, low $-38.925M), average SG&A $2.3M (high $2.31M, low $2.3M), and average EPS is $-0.902 (high $-0.902, low $-0.902). CKPT's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $73.06M (high $73.06M, low $73.06M), average EBITDA is $-73.055M (high $-73.055M, low $-73.055M), average net income is $10.36M (high $10.36M, low $10.36M), average SG&A $2.53B (high $2.53B, low $2.53B), and average EPS is $0.24 (high $0.24, low $0.24).

Did the CKPT's actual financial results beat the analysts' financial forecasts?

Based on Checkpoint Therapeutics's last annual report (Dec 2022), the company's revenue was $192K, beating the average analysts forecast of $104.17K by 84.32%. Apple's EBITDA was $-53.882M, beating the average prediction of $-10.663M by 405.33%. The company's net income was $-66.915M, missing the average estimation of $-174M by -61.47%. Apple's SG&A was $8.7M, beating the average forecast of $3.61M by 141.20%. Lastly, the company's EPS was $-7.57, beating the average prediction of $-5.589 by 35.44%. In terms of the last quarterly report (Dec 2023), Checkpoint Therapeutics's revenue was $6K, missing the average analysts' forecast of $30K by -80.00%. The company's EBITDA was $-10.169M, beating the average prediction of $-30K by 33796.67%. Checkpoint Therapeutics's net income was $-19.128M, missing the average estimation of $-24.812M by -22.91%. The company's SG&A was $1.88M, beating the average forecast of $1.04M by 80.59%. Lastly, the company's EPS was $-0.69, beating the average prediction of $-0.575 by 20.00%